» Articles » PMID: 34680260

PPARγ Targets-Derived Diagnostic and Prognostic Index for Papillary Thyroid Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Oct 23
PMID 34680260
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

In most cases, papillary thyroid cancer (PTC) is highly curable and associated with an excellent prognosis. Yet, there are several clinicopathological features that lead to a poor prognosis, underscoring the need for a better genomic strategy to refine prognostication and patient management. We hypothesized that PPARγ targets could be potential markers for better diagnosis and prognosis due to the variants found in in three pairs of monozygotic twins with PTC. Here, we developed a 10-gene personalized prognostic index, designated PPARGi, based on gene expression of 10 PPARγ targets. Through scRNA-seq data analysis of PTC tissues derived from patients, we found that PPARGi genes were predominantly expressed in macrophages and epithelial cells. Machine learning algorithms showed a near-perfect performance of PPARGi in deciding the presence of the disease and in selecting a small subset of patients with poor disease-specific survival in TCGA-THCA and newly developed merged microarray data (MMD) consisting exclusively of thyroid cancers and normal tissues.

Citing Articles

Vitamin C in the Management of Thyroid Cancer: A Highway to New Treatment?.

Gorini F, Tonacci A Antioxidants (Basel). 2024; 13(10).

PMID: 39456495 PMC: 11505632. DOI: 10.3390/antiox13101242.


Exploring the advances of single-cell RNA sequencing in thyroid cancer: a narrative review.

Tan J, Awuah W, Roy S, Ferreira T, Ahluwalia A, Guggilapu S Med Oncol. 2023; 41(1):27.

PMID: 38129369 PMC: 10739406. DOI: 10.1007/s12032-023-02260-x.

References
1.
Aprile M, Cataldi S, Ambrosio M, DEsposito V, Lim K, Dietrich A . PPARγΔ5, a Naturally Occurring Dominant-Negative Splice Isoform, Impairs PPARγ Function and Adipocyte Differentiation. Cell Rep. 2018; 25(6):1577-1592.e6. DOI: 10.1016/j.celrep.2018.10.035. View

2.
Hernandez-Quiles M, Broekema M, Kalkhoven E . PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action. Front Endocrinol (Lausanne). 2021; 12:624112. PMC: 7953066. DOI: 10.3389/fendo.2021.624112. View

3.
Colaprico A, C Silva T, Olsen C, Garofano L, Cava C, Garolini D . TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2015; 44(8):e71. PMC: 4856967. DOI: 10.1093/nar/gkv1507. View

4.
Lefterova M, Haakonsson A, Lazar M, Mandrup S . PPARγ and the global map of adipogenesis and beyond. Trends Endocrinol Metab. 2014; 25(6):293-302. PMC: 4104504. DOI: 10.1016/j.tem.2014.04.001. View

5.
Peng M, Wei G, Zhang Y, Li H, Lai Y, Guo Y . Single-cell transcriptomic landscape reveals the differences in cell differentiation and immune microenvironment of papillary thyroid carcinoma between genders. Cell Biosci. 2021; 11(1):39. PMC: 7885238. DOI: 10.1186/s13578-021-00549-w. View